ASTRAZENECA PHARMA INDIA Financial Statement Analysis
|
||
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 29.17% YoY .
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 62.64 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
ASTRAZENECA PHARMA INDIA Last 5 Annual Financial Results
[BOM: 506820|NSE : ASTRAZEN]
Standalone | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹1,296 Cr | ₹1,003 Cr | ₹806 Cr | ₹814 Cr | ₹832 Cr |
Expenses | ₹1,111 Cr | ₹838 Cr | ₹719 Cr | ₹678 Cr | ₹711 Cr |
Operating Profit (Excl OI) | ₹184 Cr | ₹165 Cr | ₹86 Cr | ₹135 Cr | ₹121 Cr |
Other Income | ₹35 Cr | ₹26 Cr | ₹15 Cr | ₹13 Cr | ₹13 Cr |
Interest | ₹1.20 Cr | ₹0.63 Cr | ₹0.95 Cr | ₹1.09 Cr | ₹1.14 Cr |
Depreciation | ₹15 Cr | ₹16 Cr | ₹17 Cr | ₹20 Cr | ₹19 Cr |
Profit Before Tax | ₹220 Cr | ₹134 Cr | ₹83 Cr | ₹127 Cr | ₹114 Cr |
Profit After Tax | ₹162 Cr | ₹99 Cr | ₹62 Cr | ₹93 Cr | ₹72 Cr |
Earnings Per Share (Rs) | ₹64.60 | ₹39.72 | ₹24.64 | ₹37.32 | ₹28.88 |
PAT Margin (%) | 12.40 | 9.85 | 7.61 | 11.42 | 8.65 |
ROE(%) | 24.95 | 18.13 | 12.78 | 22.83 | 21.83 |
ROCE(%) | 33.94 | 24.49 | 17.36 | 31.24 | 34.61 |
Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
Market Cap | : | ₹ 17,245.8 Cr |
Revenue (TTM) | : | ₹ 1,387.6 Cr |
Net Profit(TTM) | : | ₹ 95.9 Cr |
EPS (TTM) | : | ₹ 38.3 |
P/E (TTM) | : | 179.9 |
Industry Peers & Returns | 1W | 1M | 1Y |
ASTRAZENECA PHARMA INDIA | 3.1% | -2.8% | 59.9% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 5.1% | 64.6% |
CIPLA | -2.1% | 3.7% | 30.8% |
DR REDDYS LABORATORIES | -2.9% | -3.7% | 20.1% |
ZYDUS LIFESCIENCES | -1% | -13.6% | 81.7% |
DIVIS LABORATORIES | 2.1% | 3.9% | 42.8% |
ASTRAZENECA PHARMA INDIA Revenues
[BOM: 506820|NSE : ASTRAZEN]
Y-o-Y | 29.17 % |
5 Yr CAGR | 11.71 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹1,296 Cr | 29.17 | |
Mar2023 | ₹1,003 Cr | 24.50 | |
Mar2022 | ₹806 Cr | -0.98 | |
Mar2021 | ₹814 Cr | -2.19 | |
Mar2020 | ₹832 Cr | - |
ASTRAZENECA PHARMA INDIA Operating Profit
[BOM: 506820|NSE : ASTRAZEN]
Y-o-Y | 11.71 % |
5 Yr CAGR | 11.18 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹184 Cr | 11.71 | |
Mar2023 | ₹165 Cr | 91.60 | |
Mar2022 | ₹86 Cr | -36.38 | |
Mar2021 | ₹135 Cr | 12.24 | |
Mar2020 | ₹121 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -13.49 % |
5 Yr CAGR | -0.47 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 14.24% | -13.49 | |
Mar2023 | 16.46% | 53.83 | |
Mar2022 | 10.7% | -35.74 | |
Mar2021 | 16.65% | 14.75 | |
Mar2020 | 14.51% | - |
ASTRAZENECA PHARMA INDIA Profit After Tax
[BOM: 506820|NSE : ASTRAZEN]
Y-o-Y | 62.66 % |
5 Yr CAGR | 22.29 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹162 Cr | 62.66 | |
Mar2023 | ₹99 Cr | 61.19 | |
Mar2022 | ₹62 Cr | -33.98 | |
Mar2021 | ₹93 Cr | 29.21 | |
Mar2020 | ₹72 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 25.89 % |
5 Yr CAGR | 9.42 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 12.4 % | 25.89 | |
Mar2023 | 9.85 % | 29.43 | |
Mar2022 | 7.61 % | -33.36 | |
Mar2021 | 11.42 % | 32.02 | |
Mar2020 | 8.65 % | - |
ASTRAZENECA PHARMA INDIA Earnings Per Share (EPS)
[BOM: 506820|NSE : ASTRAZEN]
Y-o-Y | 62.64 % |
5 Yr CAGR | 22.30 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹65 | 62.64 | |
Mar2023 | ₹40 | 61.20 | |
Mar2022 | ₹25 | -33.98 | |
Mar2021 | ₹37 | 29.22 | |
Mar2020 | ₹29 | - |
ASTRAZENECA PHARMA INDIA Return on Capital Employed (ROCE)
[BOM: 506820|NSE : ASTRAZEN]
Y-o-Y | 38.59 % |
5 Yr CAGR | -0.49 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 33.94% | 38.59 | |
Mar2023 | 24.49% | 41.07 | |
Mar2022 | 17.36% | -44.43 | |
Mar2021 | 31.24% | -9.74 | |
Mar2020 | 34.61% | - |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
Current Share Price | : | ₹6,898.3 |
Current MarketCap | : | ₹ 17,245.8 Cr |
Updated EOD on | : | Sep 06,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ASTRAZENECA PHARMA INDIA | 3.1% |
-2.8% |
59.9% |
SENSEX | -1.4% |
3.3% |
25.2% |
ASTRAZENECA PHARMA INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 250 SMALLCAP | 0.8% | 8.4% | 49.7% |
S&P BSE HEALTHCARE | 0.7% | 8.6% | 55.8% |
S&P BSE SMALL CAP | -0.1% | 7.6% | 50.7% |
S&P BSE 400 MIDSMALLCAP | -0.4% | 6.3% | 50.4% |
S&P BSE MIDSMALLCAP | -0.6% | 7% | 53.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | 0.8% | 8.5% | 53.5% |
NIFTY MID SMALL400 | -0.5% | 6.4% | 49.6% |
NIFTY500 MULTICAP 50:25:25 | -0.8% | 5.4% | 42.7% |
NIFTY 500 | -1.1% | 4.6% | 38.7% |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA Financials
How the annual revenues of ASTRAZENECA PHARMA INDIA have changed ?
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 29.17% YoY .
How the Earnings per Share (EPS) of ASTRAZENECA PHARMA INDIA have changed?
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 62.64 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs